Pharma Journalist -

Kiadis Pharma announces that the first patient has been enrolled in the HATCY Phase 3 clinical trial for ATIR101. The multinational trial will evaluate the safety and efficacy of…
Read More...

Mylan N.V. and its partner, Aspen, announced the U.S. launch of Myleran (busulfan) Injection, 60 mg/10 mL (6 mg/mL) Single-dose Vial, a generic version of Otsuka Pharmaceutical's…
Read More...

Sunovion Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) approved the New Drug Application (NDA) for Lonhala Magnair (glycopyrrolate) Inhalation Solution…
Read More...

SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticalsonto the speaker panel RNA Therapeutics 2018! Dr. James…
Read More...

Yesterday marked dosing of the first patient with type 1 diabetes in a feasibility study to evaluate the functionality and safety of an automated insulin delivery (AID) system in…
Read More...

Mylan and Biocon announced that the European Medicines Agency (EMA) has accepted for review Mylan's Marketing Authorization Applications (MAA) for proposed biosimilar trastuzumab and…
Read More...

SMi reports: Andrew Hopkins, Chief Executive at Exscientia to discuss the role of Artificial Intelligence in small molecule drug discovery at SMi’s Drug Discovery conference in March…
Read More...

GSK and Medicines for Malaria Venture (MMV) announced the submission of a new drug application (NDA) by GSK to the United States Food and Drug Administration (FDA), seeking approval of…
Read More...

Titan Pharmaceuticals announced that it has entered into a binding term sheet with L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A., pursuant to which the parties…
Read More...

Russian biotechnology company BIOCAD and Moroccan pharmaceutical company Sothema Labs announced the launch of medicines derived using the technology provided by the Russian manufacturer…
Read More...